Cytokinetics ALS drug misses primary efficacy endpoint


In a Phase 2b clinical trial evaluating the safety, tolerability and efficacy of Cytokinetics' (CYTK) tirasemtiv in ALS patients versus placebo, the drug fails to meet its primary efficacy endpoint of the mean change from baseline in the ALS Functional Rating Scale in its revised form (ALSFRS-R) compared to the average of the scores at eight and twelve weeks versus placebo (-2.98 points in the tirasemtiv group versus -2.40 in the placebo group, p=0.11).

The test group did, however, demonstrate a statistically significant reduction in the decline of Percent Predicted Slow Vital Capacity (SVC) (a measure of the strength of the skeletal muscles  responsible for breathing). The SVC declined in the control group by 8.66% versus 3.12% in the tirasemtiv group.

The Muscle Strength Mega-Score, a measure of strength combining the data from several muscle groups in each patient, declined more slowly in the test group but no point reached statistical significance.

Shares are off 8% premarket on light volume.

Comments (1)
  • Crash survivor87
    , contributor
    Comments (213) | Send Message
     
    The reaction is mild cause news are old.
    2 Jun 2014, 12:47 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs